生命科学资讯
生物技术与制药领域的最新动态
龙沙集团确定2026年普通股东大会召开日期 - TipRanks
Lonza Sets Date for 2026 Ordinary General Meeting - TipRanks
龙沙集团胶囊业务出售谈判接近尾声——Finimize报道
Lonza’s Capsules Sale Talks Are Nearing The Finish Line - Finimize
晨星：窄护城河龙沙长期前景受强劲外包药物制造需求驱动
Narrow-Moat Lonza's Long-Term Outlook Driven by Strong Outsourced Drug Manufacturing Demand - Morningstar
Switzerland’s Lonza edges closer to sale of its capsule and health ingredients business - 93.3 The Drive
龙沙集团仍计划出售其胶囊与健康配料业务
Lonza still intends to sell its capsules and health ingredients business
龙沙集团仍计划出售其胶囊与健康成分业务——Endpoints新闻
Lonza still intends to sell its capsules and health ingredients business - Endpoints News
财报电话会议记录：龙沙集团公布2025年强劲业绩，股价却小幅下跌 - Investing.com
Earnings call transcript: Lonza reports strong 2025 results, stock dips - Investing.com
Lonza预计2025年强劲增长后，2026年将保持稳定增长——Finimize
Lonza Sees Steady 2026 Growth After A Strong 2025 - Finimize
瑞士龙沙集团接近出售其胶囊与健康配料业务——路透社
Switzerland's Lonza edges closer to sale of its capsule and health ingredients business - Reuters
龙沙集团在2025年实现强劲盈利增长——医药通讯
Lonza delivers strong profitable growth in 2025 - The Pharma Letter
瑞士合同制药商龙沙预测2026年销售增长将放缓——路透社
Contract drug manufacturer Lonza forecasts slower sales growth for 2026 - Reuters
合同制药商龙沙预测2026年销售增长将放缓——wkzo.com
Contract drug manufacturer Lonza forecasts slower sales growth for 2026 - wkzo.com
龙沙集团预测核心CDMO业务至2026年销售额将增长11-12% - MSN
Lonza forecasts 2026 sales growth of 11-12% for core CDMO business - MSN
龙沙集团销售额因新合同势头增长——华尔街日报
Lonza Sales Grow on New Contract Momentum - The Wall Street Journal
龙沙集团销售额因新合同势头增长——《华尔街日报》
Lonza Sales Grow on New Contract Momentum - The Wall Street Journal
龙沙集团销售额因新合同势头增长——《华尔街日报》
Lonza Sales Grow on New Contract Momentum - The Wall Street Journal
龙沙集团销售额因新合同势头增长——《华尔街日报》
Lonza Sales Grow on New Contract Momentum - The Wall Street Journal
龙沙集团销售额因新合同势头增长——《华尔街日报》
Lonza Sales Grow on New Contract Momentum - The Wall Street Journal
龙沙集团销售额因新合约势头增长——《华尔街日报》
Lonza Sales Grow on New Contract Momentum - The Wall Street Journal